An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

• Published in: Gynecologic oncology 2017-11, Vol.147 (2), p.243-249
• Main Authors: Oliver, Kate E., Brady, William E., Birrer, Michael, Gershenson, David M., Fleming, Gini, Copeland, Larry J., Tewari, Krishnansu, Argenta, Peter A., Mannel, Robert S., Secord, Angeles Alvarez, Stephan, Jean-Marie, Mutch, David G., Stehman, Frederick B., Muggia, Franco M., Rose, Peter G., Armstrong, Deborah K., Bookman, Michael A., Burger, Robert A., Farley, John H.
• Format: Article
• Language: English
• Subjects: Adenocarcinoma, Clear Cell - drug therapy; Adenocarcinoma, Clear Cell - mortality; Adenocarcinoma, Clear Cell - pathology; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer; Carboplatin - administration & dosage; Clear cell; Cystadenocarcinoma, Serous - drug therapy; Cystadenocarcinoma, Serous - mortality; Cystadenocarcinoma, Serous - pathology; Disease-Free Survival; Female; Histology; Humans; Middle Aged; Neoplasm Staging; Ovarian; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - mortality; Ovarian Neoplasms - pathology; Paclitaxel - administration & dosage; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival; Survival Rate
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2017.08.004

•In early stage patients, PFS was better for OCCC than for SOC.•In late-stage patients, OCCC was significantly associated with decreased OS.•Treatment effect was influenced by histology. We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). We reviewed data from FIGO stage I–IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I–II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR=1.66 (1.43, 1.91; p